

Program för SHEAs årskonferens 15-16 april 2024 i Uppsala

Språket på sessionen indikeras av språket på sessionsnamnet.

The language of the session is indicated by the language used for the session name. Projects are indicated with a P whereas organized sessions are noted with a T.

Location
Moderator / Presenter
Session
Details

April 15 (Monday)

08:30-10:00	Workshop	Sal IX: Observational Methods in Medical and Health Economic Research Jonathan Siverskog, forskare HEFUU		
10:00-10:30	Coffee + Registration			
10:30-10:45	Opening Plenary	Sal X: Opening Speech Mats Larhed, vice rektor UU, Åsa By ordf SHEA, Erik Grönqvist, föreståndare HEFUU		
10:45-11:45	Keynote	Sal X: Measuring the Efficiency, Cost and Quality of Mental Healthcare Provision: Using Real-World Data to Inform Health Policy Professor Rowena Jacobs, Centre for Health Economics at the University of York		
11:45-12:45	Lunch			
12:45-13:45	Session 1	Sal X Emil Aho (KI, Region Stockholm)	Sal IX Sun Sun (Umeå)	Sal IV Gustav Kjellsson (Göteborg)
		T1. Bortom Patientregistret –Exempel på Möjligheter och Genomförande av Komplexa Observationsstudier med Detaljerad Regional Hälsodata Emilie Toresson Grip (KI, Quantify Research)	T3. Real World Evidence on Patient-Reported Outcomes: Showcase based on Scandinavia Obesity Surgery Register (SOREg) Yang Cao (Örebro)	T5. Kontinuitet i Svensk Primärvård Cecilia Dahlgren (Vård- och Omsorgsanalys) Lina Maria Ellegård (Lund)
13:45-14:00	Break			
14:00-15:00	Session 2	Sal X: Nationell + Regionala Hälsodata Harald Gyllensvärd	Sal IX: Economic Evaluation Linus Jönsson	Sal IV: Health Shocks and Prevention Erik Grönqvist
		P1. Emelie Heintz (KI, StoCHE) Validiteten av EQ-5D-5L bland patienter med inflammatorisk tarmsjukdom – en studie baserad på data från Nationellt kvalitetsregister för inflammatorisk tarmsjukdom (SWIBREG) P2. Annabelle Forsmark (Pharmalex) Kort- och Långsiktiga Direkta och Indirekta Kostnader efter Stomioperation - en Svensk Nationell Registerstudie P3. Naimi Johansson (KI) Place or Patient as the Driver of Regional Variation in Healthcare	P16. Sun Sun (Umeå) A cost-effectiveness study for comparing three systematic treatments for hormone-sensitive prostate cancer in Sweden P17. Zin Min Thet Lwin (IHE) Expanding inguinal hernia repair through non-specialist task sharing: an economic evaluation for Sierra Leone P18. Patricio Martinez (Uppsala) Cost effectiveness of proton vs photon therapy for patients with brain tumors in Sweden	P31. Mikael Elinder (Uppsala) Health consequences of PFAS in drinking water – evidence from Sweden P32. Andreea Enache (SSE) Moving Beyond the Public vs. Private Paradigm: Insights from the Ownership Structures in Swedish Primary Healthcare P33. Akib Khan (Uppsala) Sustaining Behavior Change through Learning in Preventive Health: An Experiment in Pakistan

15:00-16:15	Coffee + Poster	Sal X: Maternal and Child Health Post 1. Markus Klint (MSD) Estimating the cost-effectiveness of catch-up vaccination against HPV related disease in boys and young men 15-26 in Sweden Post 2. Ingyin Moe (Uppsala) Economic evaluations of risk-based screening strategies for breast cancer: a systematic review of economic models Post 3. Pei Ju Ho (Uppsala) Effectiveness of animal-assisted interventions for school-aged children: A systematic review Post 4. Gilson Dutra (Uppsala) How long is a gestation? A Machine Learning analysis of 1.2 million pregnancies	Sal IX: Nordic Regulatory Landscape Post 6. Anatheia Cristea (NHTA) Paying more for drugs to minimize environmental harms? Post 7. Thomas Kristensen (NHTA) The current state of alternative agreements within Nordic HTA agencies – a targeted literature review Post 8. Heloisa Ricci (Parexel) Are Pharmaceutical Companies in Scandinavia Ready for Joint Clinical Assessments?"	Sal IV: Data in Health Economics Post 10. Kristoffer Illergård (Reveal) Unique dataset facilitating real world studies on Swedish cancer patients Post 11. Olivia Ernstsson (Quantify Research) NORdic Dataset for aSThMA Research (NORDSTAR) – a Nordic research collaboration platform Post 12. Fredrik Olson (Pharmalex) Beställningsstrategier och Resultatvariation Implikationer för Användare av Socialstyrelsens Standardiserade Statistikrapport
16:15-17:15	Session 3	Sal X: Health Technology Assessments Inna Feldman P4. Jahangir Khan (Gothenburg) Challenges with economic analysis of health technology assessments (HTA)– examples from Region Västra Götaland P5. Erik Grönqvist (Uppsala) Should willingness-to-pay thresholds change with disease severity? P6. Jesus Gullon (Nordic Market Access) Acceptance of flexible survival models by TLV	Sal IX: Ekonomisk Utvärdering Anna Philipson P19. Kajsa Appelberg (Linköping) Cost-effectiveness of newborn screening for phenylketonuria and congenital hypothyroidism P20. Anna Ringborg (SBU) Using health economic analysis to assess the monetary value of the quality criterion in national vaccine tenders P21. Michaela Eklund (Linköping) Expected value of perfect implementation of Icosapent Ethyl in Sweden	Sal IV: Labor Market Health Economics Åsa By P34. Pauline Leveneur (CREST) Technological Change and Workers' Health: Evidence from France P35. Johan A. Liseth (Oslo) The economic impact of medical innovation: The case of new CGRP inhibitors for severe migraine treatment P36. Yaroslav Yakymovych (Uppsala) Who (Mis)uses the Sickness Insurance System? Evidence from a Randomized Experiment
17:30-18:00	Meeting	Sal X: SHEAs Årsmöte		
19:00	Conference Dinner at Norrland Nation			

April 16 (Tuesday)

09:00-10:00	Session 4	Sal X Mark Clements (KI) T2. Economic Evaluations of Cancer Diagnostics and Screening: Evidence to Support Decision Making Shuang Hao (KI) Xiaoyang Du (KI) Trust Muchadeyi (German Cancer Research Centre)	Sal IX Gustav Kjellsson (Göteborg) T4. Ersättningsmodeller och Ojämlighet i Vård Lina Maria Ellegård (Högskolan Kristianstad, Lund) Sofia Sveréus (KI) Sofie Vengberg (Uppsala)	
10:00-10:30	Coffee			

10:30-11:30	Keynote	Sal X: Random Acts of Medicine Professor Anupam B. Jena, Harvard Medical School		
11:30-12:30	Lunch			
12:30-13:30	Session 5	Sal X: Mental Health Sofie Persson	Sal IX: Methods in Health Economics Anna Philipson	Sal IV: Health Inequalities Harald Gyllensvärd
		P7. Helena Svaleryd (Uppsala) The Impact of Standardized Testing on Teacher Burnout P8. Daniela Andrén (Örebro) Behind Blue Eyes: Ekonomisk Värdering av att Känna Någon som Försökt Ta Sitt Liv eller Dött Genom Själv mord i Sverige P9. Inna Feldman (Uppsala) Economic burden of suicide in Sweden in 2022	P22. Zun Yuan Zheng (Uppsala) Does Adversity Breed Compassion? Exploring the Effect of Cancer Experience on Charitable Giving Behavior P23. Sun Sun (Umeå) The EQ-5D as an Add-On Generic Health Measure in Psoriasis Patients: Psychometrical Evidence on its Added Value in a Representative Swedish Cohort P24. Ingyin Moe (Uppsala) Excess resource use and costs associated with mental health problems in children: a longitudinal register-based study of preschoolers followed until adolescence	P37. Elisavet Iliadi (Uppsala) Sick of becoming a parent: The child penalty on parent's mental ill-health P38. Jakob Granath (Uppsala) Toxic Metal Injustice? Socioeconomic Status at Birth and Proximity to Airborne Contamination P39. Joachim Steensbjerre (University of Southern Denmark) Socioeconomic inequality in key access points of the clinical pathway for ST-Elevation Myocardial Infarction patients in Denmark
13:30-13:45	Break			
13:45-14:45	Session 6	Sal X: Women's Health Emelie Heintz	Sal IX: Hälsoinvesteringar Birger Forsberg	Sal IV Linus Jönsson (KI)
		P10. Sarah Rosenberg (Linköping) Subsidizing contraception: Effects on take-up of highly effective contraceptives and on unintended births P11. Simon Henriksson (Uppsala) The societal costs of breast cancer in Sweden in 2019	P25. Jonathan Siverskog (Uppsala) Estimating the Returns to Health Spending in Sweden Using Changes in Regional Tax Rates P26. Gunnar Brådvik (IHE) En skattning av EUs BNP-kostnader av de icke-farmaceutiska interventionerna P27. Carl Björvang (TLV) Comparative theoretical study of pull incentives for antibiotics development	T6. Sällsynt Dyrt eller Ovanligt Värdefullt? Prissättning av Läkemedel vid Sällsynta Sjukdomar och Konsekvenser för Läkemedelsförmånen Joakim Ramsberg (Hjärnfonden) Douglas Lundin (TLV) Karolina Antonov (LIF)
14:45-15:15	Coffee			
15:15-16:15	Session 7	Sal X: Affordability and Accessibility Åsa By	Sal IX: Framtida Överväganden Joakim Ramsberg	
		P13. Pernille Winther and Louise Brøker (Danish Medicines Council) From positive opinion in the European Medicines Agency (EMA) to a decision by the Danish Medicines Council P14. Oskar Frisell (IHE) Disease modifying treatments in Alzheimer's disease: are we ready? P15. David Roesler (Institute for Advanced Studies Vienna) The socioeconomic impact of in-silico models for implantable medical devices a conceptual framework	P28. Anna Ökvist (Hjärnfonden) Hjärnkapital är det nya svarta – men tillför det värde? P29. Birger Forsberg (Region Stockholm) Att mäta sjukvårdens produktivitet: Dags för ett nytänk? P30. Daniela Andrén (Örebro), Gustav Kjellsson (Göteborg) Teaching Health Economics	
16:15-17:00	Closing Plenary	Sal X: Closing Speech Åsa By ordf SHEA, Erik Grönqvist, föreståndare HEFUU		